மருந்து பதவி ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MitoChem Therapeutics, Inc.: MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa CHARLESTON, SC / ACCESSWIRE / April 14, 2021 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to its lead compound, MC16, for treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is an inherited degenerative disease of the retina caused by genetic mutations that lead to severe vision loss and blindness. There are currently no approved treatments for RP. One of the key challenges of developing a treatment for RP is that it is not caused by a single mutation but is a composition of related diseases caused by hundreds of different genetic mutations. One of the hallmarks of retinal degeneration is mitochondrial dysfunction. Mitochondria, the powerhouse of the cell, produ

Michael voevodskyKostenloser wertpapierhandelCraig beesonDrug designation programMitochem therapeutics incDrug administrationFoundation fighting blindnessMitochem therapeuticsOrphan drug designationChief science officerChief executiveDrug designationChem therapeuticsகிரேக் பீசன்மருந்து பதவி ப்ரோக்ர்யாம்அடித்தளம் சண்டை குருட்டுத்தன்மை